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Evidence Based Medicine
What are the therapeutic options for strokes secondary
to intracranial large artery stenosis?
Maria Khan, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan.

Warfarin-aspirin symptomatic intracranial
disease trial-wasid and trial of cilostazol in
symptomatic intracranial arterial stenosis-Toss
Why are these studies important and
noteworthy?
Atherosclerotic stenosis of the major intracranial
arteries (intracranial internal carotid artery, middle cerebral
artery, vertebral artery, basilar artery) is emerging as the most
common cause of stroke worldwide. It causes 30% to 50% of
strokes in Asians and 8% to 10% of strokes in North American
Caucasians. Intracranial atherosclerosis preferentially affects
Asians, Hispanics, Far East Asians and Blacks as compared to
carotid bifurcation disease which affects whites more. The risk
of recurrent stroke is also higher than for most other stroke
subtypes and has been quoted as 15% per year.
Since intracranial atherosclerosis is the most frequent
but the most under recognized cause of stroke in our
population, it is important to evaluate the therapeutic options
for secondary stroke prevention in this subgroup of patients.
Before WASID, there was an uncertainty regarding
whether warfarin was superior to aspirin for secondary

Vol. 61, No. 2, February 2011

prevention in intracranial disease. Prior studies had shown
mixed results and there was a need for a randomized trial in this
regard.
The other study TOSS was undertaken to assess
whether cilostazol (which is a phosphodiesterase 3 inhibitor
with both antiplatelet and vasodilating effects) can delay the
progression of intracranial atherosclerosis and hence prevent
recurrent events.

Who were the participants?
WASID was an investigator-initiated, randomized,
double-blind, multicenter clinical trial conducted at 59 sites in
North America. Patients were recruited if they had a TIA or a
nondisabling stroke that occurred within 90 days before
randomization and that was attributable to angiographically
verified 50 to 99 percent stenosis of a major intracranial artery
(carotid, middle cerebral, vertebral, or basilar).Patients were
excluded if they had other causes for stroke like extracranial
large artery disease or cardioembolic causes. They were also
excluded if they had contraindication to Aspirin or Warfarin.
Since the study was carried out in North America most of the
patients were whites~58% with only about 30% who were
blacks.
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TOSS was also a multicenter, double blind placebo
controlled trial carried out in 5 tertiary hospitals in South
Korea. Patients with ischaemic strokes within 2 weeks from
onset, and with symptomatic stenosis in the M1 segment of
MCA or basilar artery were eligible for enrolment. They
excluded patients with other potential causes of stroke and with
anaemia and thrombocytopenia.

What was the intervention?
In WASID the initially prescribed dose of warfarin (or
its placebo) was 5 mg daily, and that of enteric-coated aspirin
(or its placebo) was 650 mg twice daily. A total of 569 patients
were randomized, 280 to Aspirin arm and 289 to Warfarin.
Both groups were followed up for a period of approximately
1.9 years. All patients underwent blood testing for INR on a
monthly basis and the dose of warfarin was then adjusted by an
unblinded investigator. Patients were contacted monthly to
determine whether outcome events had occurred and were
examined after every four months. Imaging was done if an
event was suspected.
In TOSS participants were randomly given either
cilostazol 100 mg twice daily or matching placebo. All
participants got Aspirin 100 mg daily. A total of 135 patients
were randomized, 67 to cilostazol arm and 68 to placebo arm.
They were followed at 1, 3, 5 and 6 months.

What was the outcome?
In WASID, the primary end point (which was
ischaemic stroke, brain haemorrhage or death from vascular
causes) occurred in 22.1 percent of the patients in the aspirin
group and 21.8 percent of those in the warfarin group (hazard
ratio, 1.04; 95 percent confidence interval, 0.73 to 1.48;
P=0.83). There were no significant differences between the two
groups in terms of the secondary endpoints either. Warfarin
group had significantly more cardiac events compared to those
getting aspirin (rate, 2.9 percent in the aspirin group vs. 7.3
percent in the warfarin group; hazard ratio, 0.40; 95 percent
confidence interval, 0.18 to 0.91; P=0.02). Also, major
haemorrhages occurred significantly more often among
patients assigned to warfarin (3.2 percent in the aspirin group
vs. 8.3 percent in the warfarin group; hazard ratio, 0.39; 95
percent confidence interval, 0.18 to 0.84; P=0.01).
In TOSS the primary outcome was the progression of
symptomatic stenosis on MRA at 6 months. The extent of
stenosis was graded and progression was defined as worsening
of stenosis by 1 or more grades on final MRA. The progression
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of stenosis assessed by TCD was used as a secondary outcome
measure. During the follow up period no clinical events
(strokes or TIAs) occurred. The progression on MRA was
significantly less frequent in the cilostazol group than in the
placebo group (p=.008). TCD evaluations were also similar
with less frequent progression in the cilostazol group.

What were the conclusions?
Before WASID it was thought that certain high-risk
patients such as those with severe stenosis, vertebrobasilar
disease and those who have failed anticoagulation would
benefit from warfarin. In WASID, however, patients with
severe stenosis or those previously on antithrombotic therapy
did not benefit from warfarin. Patients with basilar artery
stenosis in WASID did appear to have a lower rate of the
primary end point on warfarin, but there was no difference in
the rate of stroke in the territory of the basilar artery between
patients on aspirin versus warfarin and there was no clear
evidence of a benefit of warfarin over aspirin for patients with
vertebrobasilar stenosis.
TOSS concluded that cilostazol combined with aspirin
may prevent the progression of intracranial atherosclerotic
lesions although whether this translates into clinical effects
cannot be judged from this trial.

How does this impact our clinical practice?
Intracranial atherosclerosis is a greatly underrecognized cause of ischaemic stroke in our population.
Currently available data does not prove a clear superiority of
any one antithrombotic agent over the others. The three
agents evaluated so far for this disease entity are aspirin,
warfarin and cilostazol. Till more data becomes available,
aspirin alone is sufficient for secondary stroke prevention in
large artery atherosclerotic disease, although cilostazol
shows promise. It is, therefore, important to recognize that
other risk factors must be aggressively managed in these
patients as they may have a greater effect on slowing the rate
of progression of this disease.
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